Sionna Therapeutics (NASDAQ:SION) Coverage Initiated by Analysts at Lifesci Capital

by · The Markets Daily

Investment analysts at Lifesci Capital assumed coverage on shares of Sionna Therapeutics (NASDAQ:SION – Get Free Report) in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set an “outperform” rating and a $60.00 price target on the stock. Lifesci Capital’s target price indicates a potential upside of 40.09% from the company’s previous close.

Other equities analysts also recently issued reports about the stock. Royal Bank Of Canada restated an “underperform” rating and issued a $24.00 target price on shares of Sionna Therapeutics in a research note on Monday, December 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a research note on Monday, December 15th. Jones Trading assumed coverage on Sionna Therapeutics in a research report on Monday, September 8th. They set a “buy” rating and a $46.00 target price for the company. Raymond James Financial reiterated a “strong-buy” rating on shares of Sionna Therapeutics in a report on Wednesday, November 5th. Finally, Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $43.14.

Get Our Latest Report on SION

Sionna Therapeutics Stock Performance

SION stock traded up $0.41 during midday trading on Tuesday, reaching $42.83. The company’s stock had a trading volume of 32,204 shares, compared to its average volume of 235,942. The stock has a fifty day simple moving average of $39.06 and a two-hundred day simple moving average of $27.61. Sionna Therapeutics has a 1 year low of $7.26 and a 1 year high of $45.00. The firm has a market capitalization of $1.91 billion and a price-to-earnings ratio of -8.79.

Sionna Therapeutics (NASDAQ:SION – Get Free Report) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.06.

Insiders Place Their Bets

In related news, Director Peter A. Thompson sold 875 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $44.49, for a total transaction of $38,928.75. Following the sale, the director owned 3,595,011 shares of the company’s stock, valued at $159,942,039.39. This trade represents a 0.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Orbimed Advisors Llc sold 875 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $44.49, for a total transaction of $38,928.75. Following the sale, the director directly owned 3,595,011 shares of the company’s stock, valued at approximately $159,942,039.39. The trade was a 0.02% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 1,608,591 shares of company stock valued at $58,478,956 over the last 90 days. 3.90% of the stock is currently owned by company insiders.

Institutional Trading of Sionna Therapeutics

Institutional investors have recently bought and sold shares of the stock. Siren L.L.C. purchased a new position in Sionna Therapeutics during the first quarter valued at approximately $3,400,000. Zimmer Partners LP acquired a new stake in shares of Sionna Therapeutics during the 1st quarter worth approximately $2,484,000. Goldman Sachs Group Inc. purchased a new position in shares of Sionna Therapeutics during the 1st quarter valued at approximately $667,000. Alyeska Investment Group L.P. acquired a new position in shares of Sionna Therapeutics in the 1st quarter valued at $1,948,000. Finally, Prudential Financial Inc. boosted its holdings in Sionna Therapeutics by 114.6% during the second quarter. Prudential Financial Inc. now owns 135,185 shares of the company’s stock worth $2,345,000 after buying an additional 72,185 shares in the last quarter.

About Sionna Therapeutics

(Get Free Report)

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

Read More